Uscom
- Home ›
- AU ›
- Healthcare
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. The last earnings update was 54 days ago. More info.
Add to Portfolio Compare Print
- Uscom has significant price volatility in the past 3 months.
UCM Share Price and Events
7 Day Returns
1 Year Returns
UCM Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Uscom (UCM) | 3.2% | 3.2% | 33.3% | -20% | -20% | -42.9% |
| AU Medical Equipment | 4.1% | -0.5% | 1.1% | -3.3% | 38.7% | 103.7% |
| AU Market | -0% | 1% | 6.3% | 4.9% | 18.2% | 4.8% |
1 Year Return vs Industry and Market
- UCM underperformed the Medical Equipment industry which returned -3.3% over the past year.
- UCM underperformed the Market in Australia which returned 4.9% over the past year.
UCM Value
Is Uscom undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Uscom. This is due to cash flow or dividend data being unavailable. The share price is A$0.16.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Uscom's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Uscom's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$-0.01 |
| ASX:UCM Share Price ** | ASX (2019-04-17) in AUD | A$0.16 |
| Australia Medical Equipment Industry PE Ratio | Median Figure of 8 Publicly-Listed Medical Equipment Companies | 33.38x |
| Australia Market PE Ratio | Median Figure of 544 Publicly-Listed Companies | 16.14x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Uscom.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:UCM Share Price ÷ EPS (both in AUD) = 0.16 ÷ -0.01 |
-13.81x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Uscom is loss making, we can't compare its value to the AU Medical Equipment industry average.
- Uscom is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does
Uscom's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -13.81x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| Oceania Medical Equipment Industry PEG Ratio | Median Figure of 5 Publicly-Listed Medical Equipment Companies | 2.62x |
| Australia Market PEG Ratio | Median Figure of 360 Publicly-Listed Companies | 1.35x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Uscom, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Uscom's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$0.03 |
| ASX:UCM Share Price * | ASX (2019-04-17) in AUD | A$0.16 |
| Australia Medical Equipment Industry PB Ratio | Median Figure of 30 Publicly-Listed Medical Equipment Companies | 2.72x |
| Australia Market PB Ratio | Median Figure of 1,676 Publicly-Listed Companies | 1.67x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:UCM Share Price ÷ Book Value per Share (both in AUD) = 0.16 ÷ 0.03 |
5.33x |
* Primary Listing of Uscom.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Uscom is overvalued based on assets compared to the AU Medical Equipment industry average.
Value checks
We assess Uscom's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Uscom has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
UCM Future Performance
How is Uscom expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uscom has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Uscom's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Uscom's earnings growth to the Australia market average as no estimate data is available.
- Unable to compare Uscom's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| Australia Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 13.2% |
| Australia Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 8.4% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 6.6% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 3 | -1 | -2 |
| 2018-09-30 | 3 | -1 | -2 |
| 2018-06-30 | 3 | -2 | -2 |
| 2018-03-31 | 3 | -1 | -2 |
| 2017-12-31 | 3 | -1 | -2 |
| 2017-09-30 | 3 | -1 | -2 |
| 2017-06-30 | 3 | -1 | -2 |
| 2017-03-31 | 3 | -1 | -2 |
| 2016-12-31 | 3 | -1 | -2 |
| 2016-09-30 | 3 | -1 | -2 |
| 2016-06-30 | 3 | -1 | -2 |
| 2016-03-31 | 3 | -2 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Uscom Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.01 |
| 2018-09-30 | -0.01 |
| 2018-06-30 | -0.02 |
| 2018-03-31 | -0.02 |
| 2017-12-31 | -0.02 |
| 2017-09-30 | -0.02 |
| 2017-06-30 | -0.02 |
| 2017-03-31 | -0.02 |
| 2016-12-31 | -0.02 |
| 2016-09-30 | -0.02 |
| 2016-06-30 | -0.02 |
| 2016-03-31 | -0.02 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Uscom's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Uscom has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
UCM Past Performance
How has Uscom performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Uscom does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Uscom's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Uscom's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Uscom Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 2.92 | -1.63 | 4.04 | |
| 2018-09-30 | 2.89 | -1.80 | 4.12 | |
| 2018-06-30 | 2.86 | -1.96 | 4.21 | |
| 2018-03-31 | 2.94 | -2.00 | 4.25 | |
| 2017-12-31 | 3.02 | -2.04 | 4.29 | |
| 2017-09-30 | 3.26 | -1.92 | 4.43 | |
| 2017-06-30 | 3.50 | -1.80 | 4.58 | |
| 2017-03-31 | 3.43 | -1.86 | 4.57 | |
| 2016-12-31 | 3.36 | -1.92 | 4.56 | |
| 2016-09-30 | 3.15 | -1.92 | 4.35 | |
| 2016-06-30 | 2.94 | -1.92 | 4.13 | |
| 2016-03-31 | 2.67 | -1.79 | 3.85 | |
| 2015-12-31 | 2.41 | -1.66 | 3.56 | |
| 2015-09-30 | 2.22 | -1.44 | 3.21 | |
| 2015-06-30 | 2.04 | -1.22 | 2.85 | |
| 2015-03-31 | 2.07 | -1.24 | 2.78 | |
| 2014-12-31 | 2.10 | -1.26 | 2.70 | |
| 2014-09-30 | 1.74 | -1.39 | 2.59 | |
| 2014-06-30 | 1.38 | -1.52 | 2.48 | |
| 2014-03-31 | 1.02 | -1.44 | 2.33 | |
| 2013-12-31 | 0.66 | -1.35 | 2.17 | |
| 2013-09-30 | 0.65 | -1.36 | 2.20 | |
| 2013-06-30 | 0.64 | -1.37 | 2.23 | |
| 2013-03-31 | 0.68 | -1.37 | 2.26 | |
| 2012-12-31 | 0.72 | -1.36 | 2.29 | |
| 2012-09-30 | 0.79 | -1.59 | 2.55 | |
| 2012-06-30 | 0.86 | -1.82 | 2.80 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Uscom has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Uscom has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Uscom improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Uscom's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Uscom has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
UCM Health
How is Uscom's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Uscom's finances.
The net worth of a company is the difference between its assets and liabilities.
- Uscom is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Uscom's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Uscom has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Uscom Company Filings, last reported 3 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 4.13 | 0.00 | 2.18 |
| 2018-09-30 | 4.13 | 0.00 | 2.18 |
| 2018-06-30 | 4.84 | 0.00 | 2.49 |
| 2018-03-31 | 4.84 | 0.00 | 2.49 |
| 2017-12-31 | 5.70 | 0.00 | 3.49 |
| 2017-09-30 | 5.70 | 0.00 | 3.49 |
| 2017-06-30 | 3.78 | 0.00 | 1.71 |
| 2017-03-31 | 3.78 | 0.00 | 1.71 |
| 2016-12-31 | 4.62 | 0.00 | 1.88 |
| 2016-09-30 | 4.62 | 0.00 | 1.88 |
| 2016-06-30 | 4.94 | 0.00 | 2.84 |
| 2016-03-31 | 4.94 | 0.00 | 2.84 |
| 2015-12-31 | 3.64 | 0.00 | 1.07 |
| 2015-09-30 | 3.64 | 0.00 | 1.07 |
| 2015-06-30 | 2.29 | 0.00 | 0.53 |
| 2015-03-31 | 2.29 | 0.00 | 0.53 |
| 2014-12-31 | 2.98 | 0.00 | 1.00 |
| 2014-09-30 | 2.98 | 0.00 | 1.00 |
| 2014-06-30 | 3.32 | 0.00 | 1.58 |
| 2014-03-31 | 3.32 | 0.00 | 1.58 |
| 2013-12-31 | 2.82 | 0.00 | 0.76 |
| 2013-09-30 | 2.82 | 0.00 | 0.76 |
| 2013-06-30 | 2.35 | 0.00 | 0.54 |
| 2013-03-31 | 2.35 | 0.00 | 0.54 |
| 2012-12-31 | 1.91 | 0.00 | 0.90 |
| 2012-09-30 | 1.91 | 0.00 | 0.90 |
| 2012-06-30 | 1.47 | 0.00 | 0.54 |
- Uscom has no debt.
- Uscom has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Uscom has sufficient cash runway for 1.7 years based on current free cash flow.
- Uscom has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 6% each year.
Financial health checks
We assess Uscom's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Uscom has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
UCM Dividends
What is Uscom's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Uscom
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Uscom's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Uscom's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Oceania Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 5 Stocks | 1.7% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 417 Stocks | 4.3% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.6% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.5% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Uscom has not reported any payouts.
- Unable to verify if Uscom's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Uscom's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Uscom afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Uscom has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
UCM Management
CEO
| COMPENSATION | A$851,447 |
| AGE | 65 |
CEO Bio
Dr. Robert A. Phillips, also known as Rob, Ph.D.(Med), MPhil (Med), FASE, DMU, AMS, FIR, is the Founder of Uscom Limited and serves as its Chief Scientist. Dr. Phillips has been the Chief Executive Officer of USCOM Ltd. since December 2011. He served as the Chief Science Officer, Director of Clinical Science and Director of Medical Science of USCOM Ltd. He is the inventor of the USCOM Monitor. He was responsible for the science, applications and clinical credentials of USCOM Ltd. Dr. Phillips' work has been peer reviewed for presentation to the world's most important cardiovascular events. He is a recognised pioneer in his field, being the first person in Australia to use digital ultrasound as a standard diagnostic system. Dr. Phillips research in Echocardiography has earned him both national and international recognition. Dr. Phillips has presented at some of the world's most prestigious cardiology conferences, including the World Congress of Echocardiography and the World Congress of Cardiology. He serves as the Chairman of Medical and Technology Advisory Board at USCOM Ltd., is responsible for the supervision of USCOM Ltd.'s research activities, clinical trials, scientific collaborations and management of USCOM Ltd.'s patent portfolio. He serves as the Executive Chairman of USCOM Ltd. He holds the following positions or is a Member of the following organisations: Dr. Phillips is a Fellow of the Institute of Radiology; Diploma of Medical Ultrasound (Cardiology); Head of the Cardiac Faculty of the Australian Institute of Ultrasound, Chair of the Cardiac Education & Standards Sub-Committee of the Australian Society of Ultrasound in Medicine, Co-coordinator and Faculty Member of the ASUM DMU Cardiology course for Australia's most prestigious ultrasound qualification and Adviser to the NSW Government on ultrasound practice funding. In addition to the above appointments, Dr. Phillips has presented the following papers in recent years: Faculty presentation in relation to the USCOM Monitor to the World Congress of Echocardiography in Seoul, Korea in May 2001, Faculty presentation to the International Society of Cardiovascular Ultrasound, Anaheim California in November 2001 and World Congress of Echocardiography, Buenos Aires, Argentina in October 2003. He is the author of over 25 patents and patent applications relating to assessment of cardiovascular performance and measurement. Dr. Phillips holds a Master of Philosophy in Medicine from the University of Queensland.
CEO Compensation
- Rob's compensation has increased whilst company is loss making.
- Rob's remuneration is lower than average for companies of similar size in Australia.
Management Team
Rob Phillips
Founder
A$851K
65
Nick Schicht
General Manager
A$226K
52
Brett Crowley
Company Secretary & Executive Director
61
2.9 yrs
Board of Directors
Brett Crowley
Company Secretary & Executive Director
61
0.7 yrs
Malcolm West
Member of Medical & Technology Advisory Board
Rob Phillips
Founder
A$851K
65
Colin Sullivan
Member of Medical & Technology Advisory Board
Stephane Carlier
Member of Medical & Technology Advisory Board
Chu-Pak Lau
Member of Medical & Technology Advisory Board
Didier Payen
Member of Medical & Technology Advisory Board
Peter Lichtenthal
Member of Medical & Technology Advisory Board
Christian Bernecker
Non-Executive Director
A$38K
7.4 yrs
Nigel Sharrock
Member of Medical & Technology Advisory Board
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by Uscom insiders in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 21. Mar 19 | Buy | Xianhui Meng | Individual | 12. Mar 19 | 19. Mar 19 | 1,450,007 | A$0.15 | A$215,032 | ||
| 14. Jun 18 | Buy | Robert Phillips | Individual | 06. Jun 18 | 06. Jun 18 | 7,000 | A$0.17 | A$1,190 | ||
Management checks
We assess Uscom's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Uscom has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
UCM News
Simply Wall St News
Uscom Limited's (ASX:UCM) Earnings Dropped -8.9%, Did Its Industry Show Weakness Too?
Assessing Uscom Limited's (ASX:UCM) past track record of performance is a valuable exercise for investors. … Today I will assess UCM's recent performance announced on 30 June 2018 and evaluate these figures to its longer term trend and industry movements. … UCM is loss-making, with the most recent trailing twelve-month earnings of -AU$2.0m (from 30 June 2018), which compared to last year has become.
Simply Wall St - – Full articleDoes The Uscom Limited (ASX:UCM) Share Price Fall With The Market?
If you're interested in Uscom Limited (ASX:UCM), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).
Simply Wall St - – Full articleWhat Type Of Shareholder Owns Uscom Limited's (ASX:UCM)?
A look at the shareholders of Uscom Limited (ASX:UCM) can tell us which group is most powerful. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Uscom is not a large company by global standards.
Simply Wall St - – Full articleWhere Uscom Limited's (ASX:UCM) Earnings Growth Stands Against Its Industry
When Uscom Limited (ASX:UCM) released its most recent earnings update (30 June 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … UCM is loss-making, with the most recent trailing twelve-month earnings of -AU$2m (from 30 June 2018), which compared to last year has become. … Furthermore, the company's loss seem to be growing over time, with the five-year earnings average of -AU$2m
Simply Wall St - – Full articleCan Uscom Limited (ASX:UCM) Improve Your Portfolio Returns?
If you are looking to invest in Uscom Limited’s (ASX:UCM), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … Different characteristics of a stock expose it to various levels of market risk. … The most widely used metric to quantify a stock's market risk is beta, and the market as a whole represents a beta of one.
Simply Wall St - – Full articleUscom Limited (ASX:UCM): Should The Recent Earnings Drop Worry You?
Today I will assess UCM's recent performance announced on 31 December 2017 and compare these figures to its long-term trend and industry movements. … Was UCM's recent earnings decline worse than the long-term trend and the industry. … UCM is loss-making, with the most recent trailing twelve-month earnings of -AU$2.04m (from 31 December 2017), which compared to last year has become.
Simply Wall St - – Full articleDoes Uscom Limited (ASX:UCM) Go Up With The Market?
A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … A stock with a beta greater than one is considered more sensitive to market-wide shocks compared to a stock that trades below the value of one. … Based on this beta value, UCM appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market.
Simply Wall St - – Full articleDoes Uscom Limited's (ASX:UCM) CEO Pay Compare Well With Peers?
Earnings is a powerful indication of UCM's ability to invest shareholders' funds and generate returns. … Therefore I will use earnings as a proxy of Phillips's performance in the past year. … Usually I would look at market cap and earnings as a proxy for performance, however, UCM's negative earnings reduces the effectiveness of this method.
Simply Wall St - – Full articleShould You Sell Uscom Limited (ASX:UCM) For This Reason?
The measure of how fast Uscom goes through its cash reserves over time is called the cash burn rate. … Not surprisingly, if Uscom continues to ramp up expenditure at this rate for the upcoming year, it’ll likely need to come to market within the next few months, given the its current level of cash reserves. … The cash burn analysis result indicates a cash constraint for the company, due to its high opex growth and its level of cash reserves.
Simply Wall St - – Full articleWho Really Owns Uscom Limited (ASX:UCM)?
Check out our latest analysis for Uscom ASX:UCM Ownership_summary Mar 16th 18 Institutional Ownership Institutional investors are one of the largest group of market participants and their buy-sell decisions on a company's stock can significantly impact prices, more so, when there are relatively small amounts of shares available on the market to trade. … Insider Ownership Another important group of shareholders are company insiders. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership level and composition in UCM is not high nor active enough to significantly impact its investment thesis.
Simply Wall St - – Full articleUCM Company Info
Description
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. It serves hospitals and other medical care locations through a network of distribution partners. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
Details
| Name: | Uscom Limited |
| UCM | |
| Exchange: | ASX |
| Founded: | 1999 |
| A$22,022,538 | |
| 137,640,866 | |
| Website: | http://www.uscom.com.au |
| Address: |
Uscom Limited 66 Clarence Street, Suite 2, Sydney, New South Wales, 2000, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | UCM | Ordinary Shares | Australian Securities Exchange | AU | AUD | 10. Dec 2003 | |
| CHIA | UCM | Ordinary Shares | Chi-X Australia | AU | AUD | 10. Dec 2003 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/22 10:32 |
| End of day share price update: | 2019/04/17 00:00 |
| Last earnings filing: | 2019/02/27 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
